Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04838652
Title Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma (Pembro-CORE)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Cologne
Indications

Hodgkin's lymphoma

Therapies

Cisplatin + Cytarabine + Dexamethasone + Pembrolizumab

Carboplatin + Etoposide + Ifosfamide + Pembrolizumab

Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.